The crisis of resistance: Identifying drug exposures to suppress amplification of resistant mutant subpopulations

被引:35
作者
Drusano, GL [1 ]
Louie, A [1 ]
Deziel, M [1 ]
Gumbo, T [1 ]
机构
[1] Ordway Res Inst, Albany, NY 12208 USA
关键词
D O I
10.1086/499046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibiotic resistance is seen in both the hospital and community settings. Approaches are required to minimize the increase in resistant strains, such as good antibiotic stewardship and the limiting of antibiotic use to appropriate circumstances. There are instances when drug dose and/or schedule can be used to minimize the probability that mutants will take over the bacterial population. Over the past several years, significant advances have been made in understanding the relationship between drug concentrations and amplification of resistant mutant subpopulations. In this review, we examine the use of preclinical models for facilitating this understanding. We also use mathematical techniques, including Monte Carlo simulation, to bridge between the identification of exposures to minimize resistance and the examination of candidate drug doses to achieve this end. Examples are provided for Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, and Mycobacterium tuberculosis. In each instance, quinolone antimicrobials were examined. More investigations with other pathogens and drug classes are required.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 32 条
[1]   In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model [J].
Allen, GP ;
Kaatz, GW ;
Rybak, MJ .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (02) :150-160
[2]   Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].
Allen, GP ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614
[3]   Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3935-3941
[4]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[5]  
Baquero F, 1997, J CHEMOTHERAPY, V9, P29
[6]   2 COMPARTMENT KINETIC-MODEL WITH MULTIPLE ARTIFICIAL CAPILLARY UNITS [J].
BLASER, J ;
STONE, BB ;
ZINNER, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :131-137
[7]   Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus [J].
Campion, JJ ;
McNamara, PJ ;
Evans, MT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :209-219
[8]   Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus [J].
Campion, JJ ;
Chung, P ;
McNamara, PJ ;
Titlow, WB ;
Evans, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2189-2199
[9]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[10]   PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40